AllDocs -> cancers

A PICTURE IS WORTHMUCH NEEDED FUNDS FOR OVARIAN CANCER FOR IMMEDIATE RELEASE TORONTO, ON August 1, 2006 – The National Ovarian Cancer Association is delighted to announce that it is one of the recipients of funds from MillionArtists.com, a website devoted to creating the world’s largest collaborative work of art while raising money for medical charities. Donor-“artists” simply log onto the site and sponsor a coloured pixel which will be added randomly to an abstract painting. Founded by, Eugene Pik and Anthony Barker, the aim is to reach a million people with this initiative. “NOCA is very excited to be a part of this creative initiative! We encourage everyone to raise the flag for ovarian cancer by choosing our colour, a teal pixel and selecting National Ovarian Cancer Association as your charity,” said NOCA Executive Director Elisabeth Ross. Please visit www.MillionArtists.com ...

2005 Ovarian Cancer Survivor Course September 10, 2005 1 “What is Ovarian Cancer ?”(Clinical and Biological Features of Ovarian Cancer ), Julian Schink, MD 2 “Screening and Early Detection,” Barbara Goff, MD 3 “Update on Clinical Trials,” David Mutch, MD 4 Panel Discussion 5 “New Drugs and the Future Treatment of Ovarian Cancer ,” Robert Coleman, MD 6 “Gene Therapy and Other Targeted Biologic Therapies,” Ronald Alvarez, MD 7 “Complementary Medicine and Quality of Life Issues,” Vivian von Gruenigen, MD 8 “Sexuality and Ovarian Cancer ,” Evelyn Larrison, RN, BSN 9 Advocacy and Legislative Update / Panel Discussion 11 “Genetic Aspects of Ovarian Cancer ,” Diljeet K. Singh, MD, DrPH 12 “The Effects of Surgical Effort on Ovarian Cancer Outcomes,” William Cliby, MD 13 “No More Sleepless Nights: Understanding and Treating Sleep Disturbances in Cancer ...

Use this report to Evaluate opportunities and risks in the ovarian cancer market by analyzing the clinical and commercial attractiveness of key drug regimens www.datamonitor.com/healthcare A Datamonitor report Stakeholder Opinions: Ovarian Cancer - Growing importance as secondary indication for targeted therapies Published: Jun-06 Product Code: DMHC2181 Providing you with: • Overview of disease including epidemiology, biology of ovarian cancer , staging and prognostic factors • Review of current treatment controversies and physician opinion of existing and future treatment strategies • Evaluation of key drug regimens currently used in first, second and third line for ovarian cancer • Assessment of late-phase drugs in development for ovarian cancer including key opinion leaders' view ...

ovarian cancer 1581 Ovarian Cancer : Diagnosis and Screening in Primary Care Elise M. Hughes-Watkins, M.D. November 30, 2001 Ovarian Cancer : Burden of suffering 4 th leading cause of cancer death in women in the U.S. (after lung, breast and colon) Overall 5-year survival rate is 35% The “silent killer”: asymptomatic in early stages 75% diagnosed with advanced stage disease; 5-year survival only 10-28% Woman’s lifetime risk of dying from ovarian cancer is 1.1% Cancer Incidence and Deaths in U.S.Women in 2000 Adapted from Paley,P, Screening for the major malignancies affecting women: Current guidelines. Am J Obstet Gynecol 2001;184: 4,600 12,800 Cervical 6,500 ...

Table 1: Average Annual Number and Percent of New Invasive Cancer Cases by Site/Type Among Females in Ohio, 1997-2001 Source: Ohio Cancer Incidence Surveillance System, Ohio Department of Health, 2004. Technical Note: Ovarian cancer cases were defined as follows: International Classification of Diseases for Oncology, Third Edition (ICD-O-3), code C569, excluding histology types 9590-9989. Ovarian Cancer In Ohio, 1997-2001 August 2004 This Report on Ovarian Cancer Con- tains: • Case Counts and Rates by County of Residence • Age-specific Incidence Rates by Race • Proportion of Cases and Survival by Stage at Diagnosis and Race • Rates in Ohio com- pared to the US by Race • Risk Factors • Sources of Additional Information Ovarian Cancer Incidence and Mortality Ovarian ...